Irisin, a myokine that promotes energy expenditure [23], has also been shown to improve hepatic steatosis by activating AMP-activated protein kinase and by inhibiting transcription of sterol regulatory element-binding transcription factor 2 in hepatocytes [24]. The gene discussed is SREBF2; the disease is fatty liver disease.